Virbac reported consolidated sales results for the fourth quarter and year ended December 31, 2016. Consolidated sales in the fourth quarter amounted to EUR 225.7 million, a significant +9.2% growth compared to the same period of 2015 and a +8.6% increase at constant scope. Growth was driven primarily by sales in the United States of historical ranges, including internal parasitic ides as well as dentals and dermatology ranges. Good performances in Italy, Spain, Australia, and China also contributed to growth. For the year company reported sales amount to EUR 871.9 million compared to EUR 852.6 million last year, 2.3% overall growth, of which +4.5% excluding unfavorable exchange rates impact. All regions show positive developments with the exception of Chile. In the United States, historical ranges, including dentals and dermatology, continued to grow. The Iverhart Plus and Iverhart Max range of internal parasitic ides benefited from a favorable base effect over the year and showed a good increase compared to the same period of 2015.